Personalized Medicine Drives Guillain-Barre Syndrome Drugs Market Growth Driving Market Acceleration in the Guillain-Barre Syndrome Drugs Industry, 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Guillain-Barre Syndrome Drugs Market Size By 2025?
The market size for drugs addressing guillain-barre syndrome has seen considerable growth in the past few years. The growth trajectory is set to continue and expand from $1.17 billion in 2024 to $1.26 billion in 2025, marking a compound annual growth rate (CAGR) of 8.2%. The previously witnessed growth can be ascribed to advancements in research and development, support and initiatives from governmental programs, heightened focus on neurological and autoimmune diseases, emphasis on reducing healthcare expenses, and an increased demand for services in hospitals and clinics.

How Big Is the Guillain-Barre Syndrome Drugs Market Size Expected to Grow by 2029?
The market for drugs treating guillain-barre syndrome is anticipated to witness robust growth in the upcoming years, expanding to $1.71 billion by 2029 with a 7.9% compound annual growth rate (CAGR). The projected growth during this period can be associated with the rising prevalence of guillain-barre syndrome (GBS), increased awareness and detection rates, an aging population, a burgeoning role of hospital and retail pharmacies, and escalating demand for both oral and parenteral medications. The period is also expected to see significant trends such as the introduction of novel treatments, progression in diagnostic tools, partnerships between pharmaceutical enterprises and research organizations, advances in gene therapy, and progress in intravenous immunoglobulin therapy.

View the full report here:
https://www.thebusinessresearchcompany.com/report/guillain-barre-syndrome-drugs-global-market-report

Which Key Market Drivers Powering Guillain-Barre Syndrome Drugs Market Expansion and Growth?
The escalating need for personalized medicine is anticipated to drive the expansion of the Guillain-Barre syndrome drugs market in the future. Personalized medicine implicates customizing healthcare, based on an individual's genetics or lifestyle, to maximize benefits and minimize harmful effects. Its surging demand is fueled by its potential to provide more effective cures, developments in genomics, escalating disease complexity, and regulatory backing. Personalized medicine for Guillain-Barre syndrome looks to personalize treatments according to individual patients' profiles to enhance therapy outcomes and decrease negative effects. For example, in February 2024, as reported by the Personalized Medicine Coalition, a non-profit organization based in the US, the FDA, a US-based federal agency, endorsed 16 new personalized therapies for patients suffering from rare diseases in 2023, a significant increase from six in 2022. Therefore, the rising demand for personalized medicine is fuelling the growth of the Guillain-Barre syndrome drugs market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15581&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Guillain-Barre Syndrome Drugs Market?
In an effort to maintain their market stronghold, top businesses in the guillain-barre syndrome drugs market are making strides towards innovation by introducing novel products such as humanized monoclonal antibodies. This type of antibody combines a human antibody with a small piece of a mouse or rat monoclonal antibody and is made inside the lab. Such antibodies are being researched as potential treatments for GBS (Guillan-Barre syndrome) due to their ability to identify specific immune system components responsible for the syndrome's pathological process. For example, in October 2023, the U.S.-based clinical-stage biopharmaceutical company, Annexon Inc., announced that the EMA (European Medicines Agency) and the FDA (U.S. Food and Drug Administration) offered an orphan drug designation to ANX005 for treating GBS. This humanized monoclonal antibody, ANX005, prevents C1q, leading to an early halt to the complement-mediated inflammation and neuronal damage commonly seen with GBS. Annexon successfully filled the necessary slots for a Phase 3 trial of ANX005 in GBS and the preliminary results are anticipated in the first six months of 2024. The aim of ANX005 is to minimise inflammation and nerve damages by selectively blocking C1q activity in the nervous system. This exponential selective blocking aids in a swift halt to autoimmune damage and allows GBS patients to recover muscle strength.

What Are the Emerging Segments in the Guillain-Barre Syndrome Drugs Market?
The guillain-barre syndrome drugs market covered in this report is segmented -

1) By Drug Class: Immunoglobulins (IVIG), Corticosteroids, Plasma Exchange
2) By Treatment Type: First-Line Treatment, Adjunctive Or Supportive Treatment
3) By Application: Clinic, Hospital, Other Applications

Subsegments:
1) By Immunoglobulins (Ivig): Intravenous Immunoglobulin (Ivig) Therapy, Human Normal Immunoglobulin (Hnig), Hyperimmune Immunoglobulin Products, Ivig Formulations For Gbs Treatment, Monoclonal Antibodies As Part Of Ivig Treatment
2) By Corticosteroids: Methylprednisolone, Prednisolone, Dexamethasone, Hydrocortisone, Betamethasone, Oral Corticosteroid Formulations
3) By Plasma Exchange: Therapeutic Plasma Exchange (Tpe), Plasmapheresis Equipment For Gbs Treatment, Centrifugal Plasma Exchange, Immunoadsorption Plasma Exchange, Autologous Plasma Exchange (Ape)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15581&type=smp

Who Are the Global Leaders in the Guillain-Barre Syndrome Drugs Market?
Major companies operating in the guillain-barre syndrome drugs market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Grifols SA, Octapharma AG, Cadila Healthcare Limited, Argenx SE, Alnylam Pharmaceuticals Inc., Biotest AG, CSL Behring LLC, Kedrion Biopharma Inc., Cellenkos Inc., Annexon Inc., Hansa Medical AB, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc., Vitality Biopharma Inc., CuraVac Inc., Regenesance BV, Cresence AS, Shire Plc

Which are the Top Profitable Regional Markets for the Guillain-Barre Syndrome Drugs Industry?
North America was the largest region in the guillain-barre syndrome drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15581

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.